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Abstract: We consider optimal design of sampling schedules for binary sequence data.
The motivating example is a clinical trial where the measured responses are repeated
measurements on a binary outcome. For example, in a study of smoking cessation the
outcome could be an indicator for smoking. The decision is related to the trade-o®
between obtaining more information by more frequent sampling versus the incurred
sampling cost.
We propose an approach which allows to incorporate a variety of goals in the
utility function. We include deterministic sampling cost, a term related to predic-
tion, and if relevant, a term related to learning about a treatment e®ect. To avoid
dependence on a speci¯c parametric form we use a non-parametric probability model,
relying on minimal assumptions only. Quintana and Newton (1998) de¯ne partial ex-
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1changeability for a binary sequence. Assuming partial exchangeability the sampling
distribution can be written as a mixture of order k homogeneous Markov chains. We
use an implementation from Quintana and MÄ uller (2003) that assumes a Dirichlet
process prior for the mixture.
1 INTRODUCTION
We consider optimal sampling design for binary repeated measurements data. We
approach the sampling design as a Bayesian decision problem. The motivating ap-
plication is the choice of sampling schedules in a clinical trial with binary outcomes.
The optimal choice is a trade-o® of sampling cost for frequent observations versus the
information lost if sampling is scheduled too infrequently.
Bayesian and decision theoretic approaches to optimal design in clinical trials are
reviewed, for example, in Berry (1993), or Spiegelhalter et al. (1994). Important
applications include optimal design for dose-¯nding trials (Thall and Russell, 1998;
Whitehead and Brunier, 1995; Whitehead and Williamson, 1998), multi-arm clinical
trials (Thall et al., 1995), choice of optimal sampling times (Stroud et al., 2001), and
dose individualization (Wake¯eld, 1994). Another area of related design problems
are network design problems in spatial contexts. See, for example Clayton et al.
(1999). Optimal sampling for repeated measurements shares some features with spa-
tial network design problems, albeit the univariate action space greatly simpli¯es the
problem. We are not aware of any existing approaches speci¯cally for repeated binary
measurements.
We take a decision theoretic perspective and frame the optimal sampling design
problem as expected utility maximization. The general setup of Bayesian decision the-
oretic designs is laid out, for example, in DeGroot (1970) or Berger (1985). Chaloner
and Verdinelli (1995) and Verdinelli (1992) review applications of Bayesian design.
The main elements of a decision problem are a set of possible actions d 2 D, a prob-
ability model pd(yjµ) for future data y, a prior distribution p(µ) for the parameters
and a utility function u(d;µ;y) that speci¯es the worth of decision d for assumed
2values of parameters µ and data y. The sampling model pd(yjµ) typically depends
on the chosen action d, but the prior probability model usually does not. Therefore
we include no d subindex in p(µ), although little changes if it does. Often deci-
sions are made conditional on some pilot or historical data yo, changing the relevant
probability models to pd(yjµ;yo) and p(µjyo). It can be argued (DeGroot, 1970) that
a rational decision maker should choose the action that maximizes expected utility
U(d) =
R
u(d;µ;y) dpd(µ;yjyo). The approach we propose to optimal sampling for
repeated binary measurements follows this paradigm.
The choice of sampling times is intrinsically linked with the nature of the se-
rial dependence in the observed binary sequence. It is therefore important that the
underlying probability model make no overly strict parametric assumptions unless
they re°ect genuine prior information. We will use a class of °exible non-parametric
models for binary sequences introduced in Quintana and MÄ uller (2003), who build on
Quintana and Newton (1998) to de¯ne models for partially exchangeable sequences of
random order k. The notion of order k partial exchangeability introduced in Quintana
and Newton (1998) is a generalization of the traditional notion of exchangeability to
dependent binary sequences. A representation result similar to de Finetti's repre-
sentation theorem for in¯nite exchangeable sequences allows to consider probability
models for repeated binary sampling that are based on invariance under a slightly less
restrictive class of permutations than that implied by the symmetry of exchangeability
assumptions.
In Section 2 we formally state the decision problem, still without reference to a
particular probability model. In Section 3 we develop a semi-parametric probability
model for repeated binary measurements. The model includes a regression on covari-
ates, for example a treatment e®ect in a clinical trial application. In Section 3.2 we
discuss implementation issues, including Monte Carlo and Markov chain Monte Carlo
(MCMC) simulation. We conclude with an application example in Section 4.
32 THE DECISION PROBLEM
2.1 The Design Criterion
We start the formal description of the decision problem with a discussion of the design
criterion, i.e., the utility function. The proposed criterion includes a deterministic
sampling cost, a term related to predicting the response for a future patient, and a
term related to learning about treatment e®ects. The criterion does not depend on
speci¯c features of the underlying probability model. In the following discussion we
only need to assume some minimal structure for this model. Actual implementation
of course requires to adopt a model. Later, in Section 3 we will introduce the model
used in our implementation.
To simplify notation and terminology we describe our design approach assuming
an application to a clinical trial design where each patient gives rise to a sequence of
binary observations. Let yij 2 f0;1g denote the responses for patient i at time j, i =
1;:::;N and j = 1;:::;ni. Write yi = (yij;j = 1;:::;ni) for i = 1;:::;N. We assume
a mixed e®ects model with patient speci¯c random e®ects ®i, ¯xed e®ects ¯, occasion
speci¯c covariates wij, patient speci¯c covariates xi and possibly hyperparameters Á:
yi » p(yijwij;xi;®i;¯); ®i » p(®ijxi;Á); p(¯;Á); (1)
For example, the longitudinal data model p(yijwij;xi;®i;¯) could be a Markov chain
with transition probabilities parametrized by (®i;¯). The random e®ects distribution
could be a regression on treatment indicators xi, completed with a hyperprior on ¯
and Á. The probability model introduced later, in Section 3, has a similar structure,
with speci¯c choices for the Markov chain transition probabilities and the random
e®ects model p(®ijxi;Á). We allow regression on patient speci¯c covariates xi at
the level of both, the random e®ects distribution p(®ij:::) and the sampling model
p(yijj:::).
We do not include a probability model for xi and wij. As usual in regression
models we assume that the mechanism of assigning covariates is independent of the
hyperparameters (¯;Á), random e®ects ®i and responses yij and is therefore irrelevant
4for posterior inference. However, in the design problem we need to consider the prior
predictive distribution of future data. In this context we will assume that there is
a known mechanism to generate covariates. In the example we use resampling from
the covariates of patients in a previous trial. Alternatively, one could assume some
deterministic process to assign covariates to future patients.
Some data might already be available at the time of decision making, for example
an earlier study, or preliminary pilot data. Assume patients i = 1;:::;No, No < N
are already observed. If patients can not be considered exchangeable across studies,
a study-speci¯c random e®ect can be included in ®i. Use No = 0 for no historical
data.
After observing the ¯rst No patients we wish to decide on a sampling schedule for
the future patients i = No + 1;:::;N. A sampling schedule could be, for example,
to record yij;j = 1;3;5;:::;ni: We use d to generically denote the sampling design
and partition the data vector into (yo;yd;yc), where yo = (yij;i = 1;:::;No) is the
observed data from the ¯rst study, yd are the responses of future patients that will
be observed under design d, and yc are the responses of future patients that will
not be observed under design d. Also, we will use y = (yc;yd), µ = (®;¯;Á), and
µo = (®i; i = 1;:::;No) to denote data and random e®ects speci¯c to the new and
old study, respectively, where ® = (®i; i = No + 1;:::;N). Note that ¯xed e®ects ¯
and hyperparameters Á are included in µ. We might parametrize the sampling design,
for example, by letting d denote the sampling frequency, with d = 1 indicating that
all responses are observed, d = 2 indicating that every 2nd observation is observed,
etc. Then yd = (yij; i = No + 1;:::;N; j = 1;1 + d;1 + 2d;:::;nj). But the
sampling design d might be more complicated, including, for example, more frequent
sampling in the ¯rst few periods and longer periods between later observations. The
only constraint of the proposed approach is that the number of considered sampling
designs be moderately small, say less than 100. The constraint is imposed by the
need for simulation based evaluation of expected utilities for each possible design.
Choice of an optimal sampling design requires the de¯nition of a utility function
5that quanti¯es what alternative designs are worth. We start by de¯ning a utility
function u(d;y;µ) for an observed experiment (y;µ), i.e., the value of the design d for
hypothetical future data y and parameters µ. The ¯rst term of the utility function
is a deterministic sampling cost C1(d), for example c1 ¢ jdj, where jdj is the number
of observations under design d. The second term introduces a penalty Rij(yij;yd) for
residuals in predicting the responses yij for sampling times j that are not observed
under design d. For example, this could be jyij ¡E(yijjyd)j. The third term is related
to estimating treatment e®ects. It is only included if one of the patient speci¯c
covariates xi is a treatment indicator. Without loss of generality assume xi = 0
for placebo and xi = 1 for patients administered an experimental treatment under
consideration. We use a statistic Tij that quanti¯es learning about the treatment
e®ect. For each patient i, we assume that the study includes a matching patient i0
with identical covariates, but opposite treatment, xi0 = 1 ¡ xi. If this is not already
true we can always augment the future data y to include a patient i0 with such
covariates. Of course, this hypothetical patient should then not be included in the
¯rst two terms of the loss function. To simplify notation we write y0
ij for yi0;j and y0
i
for yi0. The measurement y0
ij is the response that we could have observed for patient
i if the treatment assignment was reversed. We de¯ne
Tij(yij;y
0
ij;yd) =
¯
¯£
E(yijjyd) ¡ E(y
0
ijjyd)
¤
¡
£
yij ¡ y
0
ij
¤¯
¯:
In words, Tij is the absolute error in estimating the treatment e®ect for patient i,
time j, with treatment e®ect de¯ned as the di®erence between mean response under
the treatment versus no treatment for patient i.
In summary, we use
u(d;y;µ) = ¡C1(d) ¡ c2
1
jI1j
X
(ij)2I1
Rij(yij;yd) ¡ c3
1
jI2j
X
(ij)2I2
Tij(yij;y
0
ij;yd) (2)
with the three terms corresponding to sampling cost, prediction and learning about
treatment e®ects. Here jIjj denotes the cardinality of the set Ij. I1 is some subset
of responses which are not observed under design d. For example, I1 = f(i;j); i =
6N;yij 2 ycg, i.e., we might use prediction for the missing responses of the last patient
as design criterion. Since patients are a priori exchangeable this is equivalent to con-
sidering prediction for all responses missing under design d, i.e., I1 = f(i;j); yij 2 ycg.
Similarly, I2 indexes some subset of the responses in the new study. For example,
we might use I2 = fN;nNg to design for the treatment e®ect in the last period for
the last patient. The optimal design d¤ is formally de¯ned by maximizing expected
utility U(d) = E[u(d;y;µ)]. The expectation is with respect to the joint distribu-
tion p(µ;y) = p(µ)p(yd;ycjµ) on parameters and data (including latent data yc). If
the decision is made conditional on some already observed data yo, the appropriate
distribution is the joint posterior (predictive) distribution p(µ;yd;yc j yo), and the
conditional expectations E(yij j yd) in the de¯nition of Rij and Tij are replaced by
E(yij j yd;yo). Exploiting conditional independence in (1)
U(d) =
Z
u(d;y;µ)p(yjµ)p(µjyo)dµdy: (3)
Although u(¢) as de¯ned in (2) involves only y and no µ, it is technically convenient to
augment the expected utility integral to an integral with respect to p(y;µjyo) instead
of p(yjyo). The augmented integral is easier to evaluate because posterior predictive
simulation from p(yjyo) is typically implemented in a two step procedure: simulating
µ » p(µjyo) and then y » p(yjµ). Also, the augmentation with µ greatly simpli¯es the
evaluation of the conditional expectations in u(d;y;µ), as we will show below.
2.2 Evaluating Expected Utility
Substituting (2) into (3) the expected utility becomes
U(d) = ¡C1(d) ¡
Z (
c2
jI1j
X
I1
Rij(yij;yd) +
c3
jI2j
X
I2
Tij(yij;y
0
ij;yd)
)
dp(y;µjyo): (4)
We evaluate (4) by Monte Carlo simulation for the integral with respect to p(y;µ j yo),
together with nested MCMC simulation to evaluate E(yij j yd;yo) for use in Tij and
Rij. We argue below how the setup of (4) greatly simpli¯es the implementation of this
7MCMC. We generate simulated experiments (µ(h);y(h)) » p(µ;yjyo), h = 1;:::;H,
from the joint probability model on parameters µ and data y, evaluate the integrand
v(µ
(h);y
(h)) =
c2
jI1j
X
I1
Rij(y
(h)
ij ;y
(h)
d ) +
c3
jI2j
X
I2
Tij(y
(h)
ij ;y
0(h)
ij ;y
(h)
d );
and use the sample averages of these v(µ(h);y(h)) values to estimate expected utility.
In Section 3 we discuss simulation from p(µ;yjyo) in a speci¯c probability model.
The evaluation of v(¢) requires E(yij j yd;yo) to substitute into the de¯nition of Rij
and Tij. We evaluate these posterior predictive means by a nested MCMC simulation
from p(µ;yc j yd;yo). The nested MCMC simulation greatly simpli¯es by the following
procedure. First rewrite
E(yij j yd;yo) =
Z
E(yij j µ;y¡ij) p(µ;yc j yd = y
(h)
d ;yo) dµdyc; (5)
where y¡ij = yinyij includes elements from yd and yc. We evaluate (5) by running
MCMC simulation to generate a Monte Carlo sample from the posterior predictive
p(µ;ycjy
(h)
d ;yo). The MCMC is initialized with the values (µ(h);y
(h)
c ) that are generated
to evaluate (4). But the pair (µ(h);y
(h)
c ) can be considered a draw from p(µ;ycjy
(h)
d ;yo),
since p(µ(h);y(h)jyo) = p(y
(h)
d jyo)p(µ(h);y
(h)
c jy
(h)
d ;yo), i.e., the MCMC simulation is ini-
tialized with an (exact) draw from the desired stationary distribution, and thus no
burn-in is required. By construction the chain is in equilibrium from the start.
We use Monte Carlo integration to evaluate expected utility for each design d. If
only a moderate number of possible designs are considered we can evaluate U(d) for
all of them and ¯nd the optimal design by inspection. In the application presented
in Section 4, for example, only 9 possible designs are considered. This is fairly typ-
ical for sampling designs in binary sequences. However, if the design space is more
complex, the Monte Carlo evaluation of expected utilities needs to be combined with
an appropriate maximization routine to ¯nd the optimal design.
A practically important concern is the dependence of the optimal design on the
trade-o® parameters (c2;c3). This is a generic problem in any design problem which
combines multiple goals and no simple solutions exist. As a practical approach in the
8absence of other information we suggest to proceed as follows. Consider the three
terms in the expected utility function (4), related to sampling cost, prediction and
inference loss, respectively. The additive nature of U(d) allows to evaluate each term
separately, writing U(d) = ¡C1(d) ¡ c2 R(d) ¡ c3 T(d), with the de¯nition for R(d)
and T(d) implied by the corresponding terms in (4). We propose to consider the range
of C1(d), R(d), and T(d) over all possible designs and adjust the values of c2 and c3
to achieve approximately matching ranges for each term. Also, separate evaluation of
C1, R and T allows computationally simple exploration of sensitivity of the optimal
design with respect to c2 and c3. See the discussion in Section 4 for an example.
3 THE PROBABILITY MODEL
3.1 Partially Exchangeable Binary Sequences
The discussion of the design criterion was without reference to a speci¯c probabil-
ity model, highlighting the model independent nature of the proposed approach to
choosing a sampling design. We now propose a model which is suitable for the de-
sired design problem. In choosing a probability model we face the following important
considerations. The model should not impose strict parametric assumptions. In par-
ticular, the model should be °exible with respect to serial dependence in the binary
sequence and ideally include the order of serial dependence as an explicit parameter.
The model needs to include structure to enable joint inference for yo and future data
y = (yd;yc), possibly allowing study-speci¯c random e®ects. Within these constraints
any model could be used to implement the discussed optimal design approach. In
the following discussion we propose a Bayesian non-parametric model that we sug-
gest as a default. It minimizes the model dependence of the ¯nal sampling design.
However the use of a non-parametric model is in no way critical to the proposed
sampling design choice. In fact, for the example reported in Section 4 we ¯nd that
analogous parametric models would lead to very similar expected utilities and to the
same sampling design. See the discussion at the end of Section 4.
9Based on the above considerations we use an extension of the semi-parametric
Bayesian model proposed in Quintana and MÄ uller (2003). The model assumes that
the binary sequence yi = (yij;j = 1;:::;ni) is partially exchangeable. Speci¯cally,
we assume that, conditional on k, the joint distribution of yi is invariant under any
permutation of (yij;j = 1;:::;ni) that leaves the order k transition counts unchanged.
For example, when k = 1, this means invariance under permutations that leave
the number of transitions 0 ! 0, 0 ! 1, 1 ! 0 and 1 ! 1 unaltered. Under
some additional technical conditions, it can be shown (Quintana and Newton, 1998)
that this implies that the sampling distribution is a mixture of homogeneous Markov
chains, with the mixture being with respect to the transition probabilities and the
order of dependence in the Markov chain. Consider now the transition matrix for the
i-th subject assuming an order K Markov chain. Instead of introducing parameters for
all 2K transition probabilities, we follow the more parsimonious approach described
in Quintana and MÄ uller (2003) and consider a simpli¯ed reparametrization in terms
of a log-linear model:
logit P(yij = 1jyi;j¡1;:::;yi;j¡K;®i;¯;K) = ®i0 +
X
1·`·K
®i`yi;j¡` +¯xxi +¯wwij: (6)
Here yi;j¡` are the lagged responses, xi are patient speci¯c covariates and wij are
occasion speci¯c covariates. The random e®ects vector ®i = (®i0;:::;®iK) collects all
logistic regression parameters ®i`. Additional ¯xed e®ects ¯ = (¯x;¯w) are common
across subjects. Order k dependence, k < K, is expressed by vanishing higher order
logistic regression parameters. If desired, (6) could be extended to include higher
order interactions of the type ®i`h yi;j¡` yi;j¡h, etc. Alternatively, one could de¯ne
parameter vectors ®(k) = (®`(k); ` = 1;:::;K) for each k and de¯ne ®i as the
combined vector of all ®(k). However, joint inference on ®(k) and ®(k0) for any
two di®erent k 6= k0 is meaningless. And for marginal inference on ®(k), the two
representations are equivalent.
To translate this structure into the desired partially exchangeable probability
model for yi we still need to parametrize a mixing measure for (®i;k) with respect to
10which we mix the order k homogeneous Markov chains. As a compromise between
ease of implementation and generality we use a Dirichlet process (DP) prior for ®i
and a multinomial distribution on k 2 f1;:::;Kg. DP priors are de¯ned in Ferguson
(1973). See, for example, MacEachern and MÄ uller (2000) for a recent review. De-
noting the right-hand side of (6) by logit°ij(®i;¯;k) our model can be summarized
as
yi » p(yij®i;¯;k); ®i » G; G » DP(M;G
o); k » pk(k); ¯ » p¯(¯); (7)
where i = 1;:::;N ranges over all subjects (from the old and new studies) and
p(yij®i;¯;k) =
ni Y
j=K+1
°ij(®i;¯;k)
yij[1 ¡ °ij(®i;¯;k)]
1¡yij: (8)
Here M and Go are the total mass parameter and base measure for the DP.
3.2 Posterior Predictive Simulation
Evaluation of the expected utility integrals in (4) requires posterior (predictive) sim-
ulation from p(µ;yjyo), where µ = (®i; i = No+1;:::;N;¯;k), including ¯xed e®ects
and hyperparameters (¯;k). Exploiting conditional independence, posterior predic-
tive sampling in model (7) is easily achieved by considering
p(y;µjyo) =
Z
p(yjµ)p(µjµo)p(µojyo)dµo
=
Z
p(y j µ)p(®i; i = No + 1;:::;N j µo)p(¯;k;µo j yo)dµo: (9)
We simulate from (9) by drawing in turn from each of the three distributions. Gen-
erating from p(¯;k;µo j yo) is posterior simulation conditional on the historical data.
Generating from p(®i; i = No + 1;:::;N j µo) is prior simulation for the future pa-
tient speci¯c random e®ects ®i. It is implemented as Polya urn sampling. Finally,
simulating from p(y j µ) requires generation of order k Markov chains. Details of all
three steps are described in the Appendix.
A common issue in decision problems is that the model used to simulate future
data, i.e., the probability model with respect to which expected utilities are de¯ned,
11needs more structure than the analysis model which is used to eventually derive infer-
ence conditional on the data. For example, in the regulatory environment of clinical
trial design it is common to use informative priors for the design, but conservative,
skeptical priors for the analysis. See, for example, Vlachos and Gelfand (1998) for a
discussion. We refer to the two, possibly di®erent, probability models as the design
model and the inference model. A related issue arises in designing sampling strategies
for binary sequences in the context of model (7). Posterior predictive simulation of
a new trial requires to generate ni, xi and starting values yij; j = 1;:::;K for the
Markov chain p(yi j ®i;k;¯) de¯ned in (7). The analysis model (7) does not include
any modeling for these variables. Instead of formal statistical modeling we propose
to use the empirical distribution of observed sequence lengths ni, covariates xi and
starting sequences (yij; j = 1;:::;K) from the earlier study, i.e., resample the values
from i = 1;:::;No.
4 EXAMPLE
Davis and Wei (1988) describe a bladder cancer study with No = 82 patients, and
with up to maxni = 12 observations taken every third month for each patient. Each
observation records an indicator for recurrence of bladder cancer tumors yij 2 f0;1g
for patient i in period j. The data set does not report yij for all patients and peri-
ods. For the purpose of this example we imputed the missing historical data points.
Patients are grouped into controls, xi = 0, and treatment, xi = 1. In the context of
this study we consider the problem of designing a future study. We assume the fol-
lowing prior probability model. For the DP base measure Go we assume independent
normal N(0;¾2) distributions for the logistic regression coe±cients ®`, with standard
deviation ¾ = 2. For the treatment e®ect we use ¯ » N(0;¾2) and for the order of
dependence we assume a uniform prior p(k) = 1=(K +1) for k = 0;:::;K. The total
mass parameter is ¯xed at M = 1. While it would be straightforward to extend the
model to include a prior on M, we found that the expected utility for the sampling
designs is not sensitive to the choice of M.
12We take K = 2, and yi1 and yi2, i = No + 1;:::;N, are chosen according to the
empirical distribution of the corresponding responses in the observed (¯rst) study. We
design the sampling schedule d for a future study of (N ¡ No) patients, considering
possible designs d 2 f1;2;3;4;:::;9g and with ni = 13 three-monthly responses for
all future patients, No + 1 · i · N. Here d = 1 indicates that responses will be
recorded at each possible occasion, j = 1;:::;ni, and for d = 2;:::;8 responses will
be observed at j 2 f3;3 + d;3 + 2d;:::g. For example, for design d = 2 the observed
data will be fyij; j = 3;5;7;9;11;13g while for design d = 6 recorded responses will
be fyij; j = 3;9g. For comparison we include as an additional design choice the option
of collecting no data. We label this design as d = 9 and report the corresponding
prior expected utilities.
We set up posterior predictive simulation to evaluate expected utilities in (4)
with p(y;µjyo) conditional on the ¯rst No patients from the earlier study. We ran a
chain of length 30;000. We evaluated several diagnostics implemented in the BOA
software (Smith, 2000) and found no evidence for practical convergence problems.
The multivariate potential scale reduction factor (Gelman and Rubin, 1992) was
evaluated as 1.004, including k, ¯, and the logistic regression coe±cients ®i for 4
randomly chosen patients. All parameters passed the stationarity tests proposed in
Geweke (1992) and Heidelberger and Welch (1983). Conditional on the historical
data yo we ¯nd the following posterior means and posterior standard deviations for
key parameters. The marginal posterior means for k, ¯ and N¤ are 1.4, -0.55 and
5:0, respectively. The corresponding marginal posterior standard deviations are 0:54,
0:60, and 1:59, respectively. The posterior from the old study becomes the prior for
the design study. Since posterior inference in the old study is found to be robust with
respect to the prior choices for the old study (data not shown) we conclude that the
entire design approach is robust with respect to the initial hyperparameter choices.
We simulated H = 250 posterior predictive draws (µ(h);y(h)). For each simulated
y(h) we set up a nested MCMC run to evaluate the conditional means E(yij j yd;yo).
For this nested MCMC we used 250 iterations, starting with the (true) simulated
13y
(h)
c ;µ(h). Since the chain starts in equilibrium we can accumulate ergodic averages
without any burn-in.
Table 1 reports the estimated expected utilities across alternative designs. Nu-
merical uncertainties for the reported expected utilities are all below 0:06. The ¯rst
columns report the expectations for the three terms in the utility function (2) cor-
responding to sampling cost, prediction and treatment e®ect. We use C1(d) = ¡jdj.
Figure 1 plots the values against jdj, the number of repeated measurements per pa-
tient. The terms R(d) and T(d) rise slowly from three-monthly sampling, d = 1, to
sampling every six months, d = 2. Under d = 1, by de¯nition R = 0 since yc = fg.
In both terms a critical change occurs when moving from 3 to only 2 measurements
(designs d = 5 to d = 6). The last column in Table 1 combines the three terms using
weights c2 = ¡10 and c3 = ¡5. The optimal design is found for d = 2. Little is lost
when moving to more frequent sampling, d = 1, slightly more is lost when moving to
d = 3. Dropping below 3 repeated measurements per patient is almost equivalent to
prior inference, without any data.
The proposed optimal design approach is independent of the speci¯c model. We
used a non-parametric Bayesian model as a default choice to minimize model de-
pendence of the ¯nal sampling recommendation. But the use of this non-parametric
Bayesian model is by no means critical for the proposed design approach. To ex-
plore the use of alternative models and also to investigate sensitivity of the design
choice with respect to the underlying probability model we considered two paramet-
ric models. To facilitate a comparison the models were chosen to be similar to the
non-parametric model. In particular, we de¯ned a parametric version of model (7) by
replacing the unknown random e®ects distribution G with the base measure Go. The
resulting model takes the form of longitudinal data models as in Zeger and Karim
(1991), including the lagged response yi;j¡` as occasion speci¯c covariates. The sec-
ond parametric model assumes Markov transition probabilities parametrized as in
(6), using a common ® for all patients, with ® » Go. The model is a mixture of order
k Markov chains with prior Go for the transition probabilities. We refer to the two
14Table 1: Expected utilities under alternative designs. Let R(d) and T(d) denote the
terms in (2) related to prediction and inference on the treatment e®ect, respectively.
Each row reports one design, sampling cost, R and T. Numerical uncertainties are
all below 0:06.
design d C1(d) E(Rjd) E(Tjd) U(d)
1 11 0.00 0.00 -11.0
2 6 0.15 0.29 -9.0
3 4 0.34 0.61 -10.5
4 3 0.54 1.02 -13.5
5 3 0.50 0.99 -13.0
6 2 0.99 1.87 -21.3
7 2 1.07 1.84 -21.9
8 2 0.97 1.73 -20.3
9 0 1.26 2.22 -23.7
15parametric models as models I and II. Both parametric models can be interpreted as
special cases of (7), with M ! 0 (model II) and M ! 1 (model I), respectively. Ex-
pected utilities under the two models are shown in Figure 1. While expected utilities
di®er slightly under the alternative models, the ¯nally recommended sampling design
remains unchanged.
Inference about the optimal sampling design typically involves trading o® compet-
ing goals related to prediction, sampling cost and inference loss. This is formalized
in the utility function proposed in (2). As in many biomedical decision problems
speci¯cation of the trade-o® weights c2 and c3 is a challenging problem. We have
earlier proposed a pragmatic default choice for c2 and c3. The additive nature of (2)
allows an easy implementation of informal sensitivity analysis. Separately computing
the expectations R(d) and T(d) corresponding to the second and third term in (2)
facilitates a computationally e±cient evaluation of expected utility U(d) for alterna-
tive choices of c2 and c3. Figure 2 plots expected utility using (c2;c3) equal (5;5),
(5;10) and (10;0).
5 DISCUSSION
We have proposed an approach to optimal design for repeated binary measurements.
The strengths of the proposed method are the °exibility of the underlying semi-
parametric probability model, and the generality of the design criterion. The main
limitations of the proposed approach are the assumption of equally spaced data, the
numerical evaluation of the expected utility function, and the need to de¯ne trade-o®
parameters for the competing goals of minimizing sampling cost, predicting missing
observations and optimizing inference about treatment e®ects, or other relevant sum-
maries of the probability model. The constraint to equally spaced data stems from
the underlying probability model. The Markov chain model would be inappropriate
for unequally spaced data.
The numerical evaluation of the expected utility function is a limitation and an
opportunity at the same time. On one hand, MCMC simulation is required to com-
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Figure 1: Expected utilities. Panels (a) and (b) show the individual terms of the
expected utility function. Panel (c) shows the expected utility using weights c2 = ¡10
and c3 = ¡5. In all three plots the points are labeled with the design number given
in Table 1. The x-axis is the number of observations per patient. The solid lines
show expected utilities under the non-parametric model. The dashed lines (with
open circles for the points) show inference under parametric model I. The dotted
lines (with triangles for the points) show expected utilities under parametric model
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Figure 2: Expected utilities under alternative weights c2 and c3. Separately comput-
ing the terms C1(d), T(d) and R(d) of the expected utility function facilitates easy
exploration of alternative weights to trade o® the competing goals.
pute expected utilities. On the other hand, the simulation based approach allows
to substitute essentially arbitrary utility functions u(d;µ;y) and thus provides great
°exibility in specifying the design criterion. For instance, the inclusion of more than
two treatment levels can be easily accommodated within the general framework dis-
cussed. To do so, we can simply add as many ¯xed e®ect coe±cients as needed,
and modify T(d) in (2) to any desired speci¯cation that re°ects learning for the new
multi-treatment scenario.
Appendix: Posterior Predictive Simulation
We describe details of the posterior predictive simulation (9). Simulating from p(y j µ)
is a straightforward generation of order k Markov chains with transition probabilities
de¯ned in (6). Recall that µo = (®i; i = 1;:::;No) are the random e®ects speci¯c
to the ¯rst No patients. Generating samples from p(®i; i = No + 1;:::;N j µo)
is accomplished by exploiting the representation of the marginal prior on ®i, i =
181;:::;N; as a Polya urn scheme (Blackwell and MacQueen, 1973). Given µo, ®No+1
is either equal to one of the components of µo with probability proportional to the
corresponding cluster size, or a draw from Go with probability proportional to M.
The remaining (®i; i = N0 + 2;:::;N) are drawn similarly, after upgrading the
con¯gurations and cluster sizes according to the result of the previous draw. See
Blackwell and MacQueen (1973) for a general description of this type of urn schemes.
Finally, generating from p(µo;k;¯ j yo) is posterior simulation for the earlier study
yo. It is implemented by standard Markov chain Monte Carlo posterior simulation
for DP mixture models. See, for example MacEachern and MÄ uller (2000) for details.
Only one move is di®erent, namely changing k. In our implementation we proceed as
follows. The discrete nature of the random measure G implies the possibility of ties
among the imputed ®i. Let f®¤
1;:::;®¤
N¤g denote the N¤ · No distinct values among
the ®i, i = 1;:::;No. We introduce con¯guration indicators si with si = j if ®i = ®¤
j.
The use of such con¯guration indicators is a standard tool in posterior simulation
for DP mixture models. Consider now a Metropolis-Hastings (MH) proposal for a
move from k to a proposed new value ~ k drawn from a uniform distribution over
fk ¡ 1;k;k + 1g \ f1;:::;Kg. Two cases arise. When ~ k = k the proposal will
have exactly the same number of nonzero auto-logistic regression coe±cients in (6).
The proposal is then generated as a series of draws from all the full conditionals,
including the con¯guration indicators s = (s1;:::;sn). In practice, this is the same
as one iteration of the usual Gibbs sampler for DP mixture models, as discussed in,
e.g. MacEachern and MÄ uller (2000). This also implies great simpli¯cations when
computing the MH acceptance ratio. When ~ k 6= k the set of nonzero coe±cients in
(6) is di®erent in the proposal and in the currently imputed µ. We de¯ne a proposal
for the next state of the Markov chain as follows. We leave the con¯gurations s
unchanged, and de¯ne proposals ~ ®¤
j by considering the conditional posterior
p(®
¤
j j s;yo;¯;k) / G
o(®
¤
j)
Y
p(yi j ®
¤
j;¯;k); (10)
where p(yi j ®¤
j;¯;k) is given in (8). The product goes over the set of indices fi : i ·
No and si = jg. We generate ~ ®¤
j from a multivariate normal approximation of (10).
19Similarly, ~ ¯ is generated from a normal approximation to the conditional posterior
for ¯ given (~ ®¤
1;:::; ~ ®¤
N¤). The joint proposal (~ k; ~ ¯; ~ ®1;:::; ~ ®N¤) is then accepted with
the appropriate MH acceptance probability. See additional details in Quintana and
MÄ uller (2003).
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